Shares of Argan Inc. (AGX) slid 6.6% to $506.45 on July 28, extending a punishing weeklong retreat that has erased roughly 17% from the stock's recent peak near $610 on July 22. No new bad news triggered the sell-off — this is a classic case of investors cashing in gains after an extraordinary run, raising the question of whether the power-plant builder's valuation still makes sense.
• A Blowout Quarter Set the Stage for a Gravity-Defying Rally
Argan's fiscal Q1 2027 results, reported June 4, were staggering: revenue hit a record $291 million, up 50.2% year over year, while earnings per share more than doubled to $3.24 and adjusted EBITDA climbed 79.2%.
The stock surged roughly 92% year to date and 155% over the past 12 months , propelled by booming demand for gas-fired power plants and data-center infrastructure. That kind of momentum invites profit-taking once the buying pressure pauses.
• The Valuation Got Ahead of the Business
Despite a robust backlog and strong earnings, the stock trades at a price-to-earnings ratio of roughly 54x trailing profits — far richer than the broader construction-services industry. The rally pushed the valuation well above the multiples of its sub-industry, the broader sector, and the S&P 500. At those levels, even a slight shift in sentiment can trigger outsized selling, which is exactly what shareholders are living through this week.
• A $2.8 Billion Backlog Gives Long-Term Holders Something to Hang On To
Argan maintains a project backlog worth $2.8 billion, spanning complex energy plants and utility-scale solar fields across multiple countries.
Operating cash flow hit $113 million last quarter, up 221% from a year ago. That pipeline offers years of revenue visibility and underpins the bull case, but execution risk is real: results hinge on a small number of large contracts, tariff-related cost pressures threaten margins, and scaling the workforce without compromising quality will be critical.
• Analysts Still See Upside — but Less Than Before
Five analysts rate the stock a "Buy" with an average 12-month target of $679.80 , implying about 34% upside from today's beaten-down price. But management itself acknowledges that award timing for new contracts remains "largely outside its control," introducing lumpiness that could test patience. For now, the pullback looks like healthy digestion of a huge rally — not a fundamental crack in a business riding the AI-era power boom.